In Brief: Everest Medical
This article was originally published in The Gray Sheet
Everest Medical: Firm plans to introduce the BiSECTOR 5 mm bipolar ligating forceps for use in coagulation of vessels during electrosurgery and to transect vessel tributaries prior to saphenous vein harvesting at the Jan. 23-25 Association of Physician Assistants in Cardiovascular Surgery meeting and the Society of Thoracic Surgery conference Jan. 26-28, both of which are being held in New Orleans. The company also is debuting an Everest-branded version of its bipolar scissors. Everest will market the instruments "for use with non-Guidant saphenous vein harvesting approaches and systems," the company says in a Jan. 20 release. The company entered a supply agreement with Guidant in June 1997 to market Everest instruments with Guidant's minimally invasive saphenous vein harvesting system...
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.